Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Exenatide and Glucagon.

The purpose of this study was to evaluate GLP-1 effects on β-cell secretory capacity, an in vivo measure of functional β-cell mass, early in the course of T2D.

Who Took Part

The study group was 40 subjects.

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

The researchers conducted a randomized controlled trial in 40 subjects with early T2D who received the GLP-1 analog exenatide (n = 14), the dipeptidyl peptidase IV inhibitor sitagliptin (n = 12), or the sulfonylurea glimepiride (n = 14) as an active comparator insulin secretagogue for 6 months.

How the Study Was Run

In design terms this was a randomized study.

The subjects were allocated by chance, so the Exenatide group and the comparison group should start out alike.

The methods mention a period of 6 months.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Exenatide, Glucagon-Like Peptide 1, Glucagon-Secreting Cells, Glucose Tolerance Test, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized study of Exenatide and Glucagon in 40 subjects over 6 months.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Diabetes care), a journal based in United States.

More context: the Exenatide compound page and the Glucagon compound page, all human trials.